RESULTS
All 79 patients who started adjuvant chemotherapy between the specified dates were included in the data capture process. Table i presents patient characteristics. Table ii presents regimen-specific fn event rates, the rates of primary and secondary g-csf prophylaxis, and the event rates after each type of prophylaxis. Figure 1 presents the distribution of the timing of fn events for fec-d and tc. Of patients experiencing a fn event, 5 did not receive secondary prophylaxis: 3 because the fn episode occurred after the last planned cycle of chemotherapy, and 2, because of early treatment discontinuation. No treatment-related deaths occurred.
Previous work has suggested that certain patient subsets may be at higher risk of fn events and that primary prophylaxis might be considered at a lower regimen-specific fn probability (for example, 10%-20%) if certain demographic or clinical risk
INTRODUCTION
We read with great interest the recent article by Madernas et al. describing the clinical experience of four regional cancer centres in Ontario with rates of febrile neutropenia (fn) stemming from adjuvant fec-d (5-fluorouracil-epirubicin-cyclophosphamide, then docetaxel) for early-stage breast cancer 1 . Those authors retrospectively reviewed the electronic and paper records of 671 patients treated at the Ottawa Hospital Cancer Centre, the Cancer Centre of Eastern Ontario, the London Regional Cancer Program, and the Northeastern Ontario Regional Cancer Centre, who had completed adjuvant fec-d chemotherapy between June 1, 2006, and December 31, 2008. They observed an overall fn event rate of 22.7% (152 in 671), which is considerably higher than that reported in the pivotal pacs 01 trial (11.2%) that led to the widespread adoption of adjuvant fec-d for node-positive early-stage disease 2 . Similar observations have been reported for tc (docetaxel-cyclophosphamide) chemotherapy, another recently introduced adjuvant regimen for early-stage breast cancer [3] [4] [5] .
Clinical practice guidelines from the American Society of Clinical Oncology and the European Society for Medical Oncology both recommend that primary prophylaxis with granulocyte colonystimulating factors (g-csf) be considered for treatment regimens with the probability of a fn event rate of 20% or higher 6, 7 . With clinical experience suggesting that fn rates during fec-d treatment are more common than reported in pacs 01, 35% of patients in the study by Madernas et al. did receive primary prophylaxis with g-csf, leading to a statistically significant reduction in the observed fn rates for those who received primary prophylaxis compared with those who did not (6.4% vs. 31.4%; relative risk: 0.20; p < 0.001).
METHODS
Because of similar concerns, and in the context of a paucity of prospectively collected data about fn event 940 factors are present 8.9 . We assessed fn event rates as a function of two of the factors most commonly reported to increase fn risk; age and the presence of comorbidities. We observed no obvious differences in fn rates according to age [<50 years: 9 in 27 (33.3%); 50-60 years: 7 in 31 (22.6%); >60 years: 7 in 21 (33.3%)] or number of comorbidities [0: 12 in 37 (32.4%); 1-2: 10 in 39 (25.6%); >2: 1 in 3 (33.3%)].
DISCUSSION
In our prospectively-assessed cohort receiving standard adjuvant chemotherapy for breast cancer, the fn incidence exceeded American Society of Clinical Oncology and European Society for Medical Oncology thresholds for consideration of primary g-csf prophylaxis and was greater than the incidence reported in the relevant clinical trials (tc: 4% for <65 years of age and 8% for >65 years of age; fec-d: 11.2%) 2, 3, 5, 6 . The fn event rates were similar across age groups and were not observed to vary by presence of 1 or more comorbidities, suggesting that elucidation of risk factors may not select patients preferentially at risk for fn because of adjuvant tc or fec-d. In the context of data reported by Madernas et al. 1 and others 4, 5 , our data suggest that fn event rates during adjuvant fec-d and tc in clinical practice are substantially higher than those reported in the pivotal clinical trials and commonly exceed clinical guideline thresholds for consideration of primary prophylaxis with g-csf for patients choosing to receive those adjuvant systemic regimens for moderate-to highrisk early-stage breast cancer.
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